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 ABSTRACT  
 
 
Novel Platforms for Cardiovascular Repair 
 
Timothy P. Martens, MD 
 
 
 Collectively the experiments discussed in this thesis represent an attempt to 
improve upon current cardiovascular cell therapy practices.  The first chapter focuses 
on the regenerative efficacy of immunoselected mesenchymal progenitor cells in the 
setting of acute myocardial ischemia.  Particular attention is paid to the mechanisms 
underlying the functional recovery attributed to administration of these cells as well 
as potential drawbacks to their delivery as a liquid suspension.  Given the poor 
engraftment witnessed with this formulation, the second chapter focuses on the use of 
in situ polymerization of hydrogels to enhance immediate cell retention and survival.  
This approach is further developed in chapter three with particular attention paid to 
the constraints imposed by currently used percutaneous delivery catheters.  The fourth 
and final chapter combines the use of hydrogels with a novel biomimetic scaffold in 
an attempt to further improve upon cell retention and survival as well as provide a 
post-implant environment that provides physical and biologic characteristics similar 
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BACKGROUND AND RATIONALE 
 
Congestive heart failure (CHF) is an enormous health problem in the US, affecting nearly 
5 million people (0.5 million newly diagnosed/yr) and imposing a significant burden on those 
afflicted (12-15 million office visits, 6.5 million hospital days and almost 0.3 million deaths/yr) 
that is surely to increase as the population ages.  While cardiac transplantation remains the 
definitive treatment for end-stage heart failure, it is seriously limited by a scarcity of available 
donor organs.  Because the capacity for cardiac tissue to repair itself is minimal at best, 
alternative approaches such as cell-based therapies for replacing, repairing or regenerating 
damaged myocardium have garnered much attention in recent years. However, the practical 
benefit of such strategies has been obscured by inconsistent preclinical data and a poor 
understanding of the mechanisms underlying perceived functional improvement following cell 
therapy.   
Over the past decade, explosive growth in the fields of vascular and developmental 
biology has led to the characterization of multiple cell types with potential for supporting 
angiogenesis, myogenesis, or both.  The cells can be loosely classified into two groups: somatic 
or adult (eg. bone-marrow and adipose derived stem cells) and embryonic.  In addition, recent 
advances have enabled the conversion of somatic cells into an embryonic-like phenotype (iPS or 
induced pluripotent stem cells). Virtually every cell type examined has shown some degree of 
efficacy in animal models although the exact mechanisms of functional recovery often remain 
unknown.  Nevertheless, results from small and large animal studies have been used to justify 
early clinical trials involving both surgical and catheter-based delivery in the acute and chronic 





As the clinical experience with cell-based therapies for both acute and chronic 
myocardial ischemia grows, a few recurring themes permeate the results of ongoing clinical 
trials.  First, while functional improvement can be demonstrated in several cardiac parameters, 
the extent of these improvements tends to be small.  When cardiac tissue can be recovered for 
analysis, cell survival is poor and differentiation into myocytes is minimal.  Finally, 
differentiation and integration seem to be relatively infrequent events with paracrine mechanisms 
dominating proposed theories of repair. To be truly effective, the next generation of cell-based 
therapy for myocardial ischemia will need to move away from “naked” cell delivery and draw 
upon tissue engineering principles to maximize clinical benefit. 
In choosing a cell source for the majority of the experiments described here, we sought to 
balance the clinical safety of the chosen cells with their potential for differentiation and repair.  
Bone-marrow mononuclear cells (or subsets thereof) have been used in the bulk of clinical trials 
to date.  While an excellent safety profile has been established for these cells, they do not appear 
capable of meaningful myogenesis in preclinical models or even in vitro.  Conversely, 
embryonic stem cells possess excellent myogenic potential but are associated with significant 
adverse events including ectopic tissue formation and tumorogenesis.  We therefore conducted 
the majority of these experiments with mesenchymal stem cells (MSCs) since they are capable of 
differentiation into multiple lineages but have not shown tumorogenic potential in preclinical 
models or in limited clinical application to date.   
Collectively the experiments discussed in this thesis represent an attempt to improve 
upon current cardiovascular cell therapy practices.  The first chapter focuses on the regenerative 
efficacy of immunoselected mesenchymal progenitor cells in the setting of acute myocardial 





attributed to administration of these cells as well as potential drawbacks to their delivery as a 
liquid suspension.  Given the poor engraftment witnessed with this formulation, the second 
chapter focuses on the use of in situ polymerization of hydrogels to enhance immediate cell 
retention and survival.  This approach is further developed in chapter three with particular 
attention paid to the constraints imposed by currently used percutaneous delivery catheters.  The 
fourth and final chapter combines the use of hydrogels with a novel biomimetic scaffold in an 
attempt to further improve upon cell retention and survival as well as provide a post-implant 
environment that provides physical and biologic characteristics most similar to native 
myocardium.  While this approach currently requires surgical intervention, technological 
































CHAPTER 1: Mesenchymal Stem Cell Therapy for Acute Myocardial Ischemia 
 
 
The discovery of circulating endothelial progenitor cells (1), their mobilization in 
response to ischemia (2), and their origin and isolation from human bone marrow (3) has 
stimulated intense translational research focused on using bone-marrow derived elements to 
regenerate ischemic myocardium.  The bone marrow compartment can be subdivided into two 
interdependent spaces – the hematopoetic cell compartment and the stroma.  The stroma is 
composed of fibroblasts, adipocytes, nerves, and the bone marrow’s vascular system which 
consists of a network of fenestrated, thin-walled vessels supported by the surrounding 
hematopoetic cells.  The hematopoetic compartment produces approximately 500 billion cells 
per day which use the bone marrow vasculature as a conduit to the systemic circulation. 
 The hematopoetic compartment contains a multitude of cell types in varying stages of 
differentiation.  Cells can be harvested for transplantation either directly by bone marrow 
aspirate or indirectly through peripheral blood mobilization.  The latter method employs G-CSF 
to stimulate mobilization followed by apheresis to isolate peripheral blood mononuclear cells 
(PBMNCs) from the circulation.  Direct bone marrow aspiration followed by density gradient 
separation of whole marrow is typically used to isolate bone-marrow mononuclear cells 
(BMMNCs).  Either method produces a heterogenous population of cells containing monocytes, 
hematopoetic stem cells, endothelial precursors, and assorted other elements.  In animal models 
of acute myocardial ischemia, immunoselected cells from the mononuclear portion of human 
bone-marrow induced angiogenesis in the infarct border zone, reduced myocyte apoptosis, and 





Mesenchymal stem cells (MSCs) represent between 0.01 and 0.001% of nucleated cells 
in adult human bone marrow but can be readily expanded in culture (4).  Unlike endothelial 
progenitors which for the most part are lineage-restricted, MSCs readily form bone, fat, cartilage, 
and myocytes in vitro (5).  In addition, a growing body of literature suggests that MSCs may be 
able to evade immune detection due in part to direct inhibition of inflammation as well as a lack 
of cell-surface costimulatory molecules (6).  These immunomodulatory properties combined 
with the ability to rapidly expand MSCs in culture raise the possibility of developing an off-the-
shelf product for myocardial revascularization. 
In the prenatal period, definitive vascular network formation to sustain embryonic 
organogenesis is dependent on influx of mesenchymal lineage cells from the dorsal aorta and 
neural crest (7-9) to form the vascular supporting mural cells such as vascular smooth muscle 
cells and pericytes. Mesenchymal lineage precursor cells have been identified to be present in the 
postnatal mammalian bone marrow, and can be reproducibly isolated and grown in culture by 
prospective immunoselection (10-13). These cells are anatomically located in perivascular niches 
in the bone marrow and throughout the body, and demonstrate phenotypic and genetic identity to 
vascular pericytes (14).  Freshly isolated multipotent human adult bone marrow mesenchymal 
lineage stem cells have been extensively characterized for a long list of surface markers.  The 
combined use of monoclonal antibodies (mAbs) against the antigens STRO-1 and VCAM-
1/CD106 results in up to 1000-fold enrichment of mesenchymal precursors capable of giving rise 
to colony-forming units of the fibroblastoid type (CFU-F) relative to their incidence in 
unseparated bone marrow.  At a clonal level, STRO-1bright VCAM-1-positive cells demonstrate 
multipotential capability, differentiating to smooth muscle, bone, cartilage, and adipose tissue.  





term survival of cardiomyocyte precursors (15), our intial experiments investigated whether 




Human mesenchymal precursor cells were isolated to greater than 99% purity from donor 
bone marrow by dual immunoselection using mAbs against STRO-1 and VCAM-1. Following ex 
vivo cellular culture and expansion for over six passages, phenotypic analysis of the cells 
demonstrated continued high-level expression of STRO-1 by 25–40% of the cultured cells, and 
these cells were immunoselected a second time using STRO-1 mAb. To evaluate whether these 
cells were capable of inducing vascular network formation in vivo, 0.5×106 culture-expanded 
STRO-1bright cells were directly injected into a rat glioblastoma tumor that produced high 
amounts of vascular endothelial growth factor (VEGF) and had been placed 2 weeks earlier in 
the subcutaneous tissue of an athymic nude rat (Figure 1-1).  Seven days later, the animals were 
killed and the glioblastoma tissue was evaluated by immunohistochemistry for evidence of 
vascular network formation. As shown in Figure 1, human mesenchymal precursor cells 
persisted in large numbers at 2 weeks in rat tissue, as defined by a mAb with specificity for 
human mitochondrial structures, and were found adjacent to and surrounding vascular structures. 
Marked induction of arteriogenesis was noted at the sites of mesenchymal precursor cell 
injection, as defined by over eight-fold greater numbers of large-caliber vessels (20–100 µm 
diameter) dually staining with mAbs against the endothelial marker von Willebrand factor (vWF) 
and [alpha]-smooth muscle actin (α-SMA), compared with saline-treated controls. Arteriogenesis 






Figure 1-1: Induction of tumor neovascularization (angiogenesis and arteriogenesis) by human STRO-
1bright cells. Athymic nude rats were irradiated with 6 Gy for 5 min to remove residual natural killer 
function, then injected subcutaneously in the flank with 1 × 106 rat glioblastoma cells. Two weeks after 
implantation, the glioblastoma tumors were directly injected with either (A) saline or (B) 0.5 × 106 STRO-
1bright cells, and animals were killed 7 days later. In consecutive sections of the tumor tissue stained by 
the immunoperoxidase method using monoclonal antibodies directed, respectively, against von 
Willebrand’s factor (vWF) and anti-smooth muscle actin (anti-SMA), animals injected with STRO-1bright 
cells demonstrated significantly greater numbers of capillaries and arterioles (defined, respectively, by 
vWF staining alone and combined expression of vWF and anti-SMA) than animals injected with saline. 
 
To investigate whether similar induction of arteriogenesis could occur in the acutely 
ischemic myocardium, culture-expanded STRO-1bright cells (0.2×106 cells or 1×106 cells), 1×106 
bone marrow cells depleted of STRO-1bright cells, or saline, were injected into the myocardium of 
athymic nude rats 48 hours after ligation of the left anterior descending coronary artery (LAD). 
Arterioles were quantitated by identifying structures coexpressing an outer layer of α-SMA-
positive cells and an inner layer of vWF-positive cells. As shown in Figure 1-2, animals injected 
with STRO-1bright cells demonstrated a dose-dependent increase in arteriolar induction in the 
ischemic heart, with the highest dose inducing three-fold greater numbers of arterioles than 






Figure 1-2:  Dose-dependent effect of STRO-1bright cells on myocardial neovascularization. To examine 
whether induction of angiogenesis and arteriogenesis could be extended to other tissues, and was 
associated with biological significance, cultured progeny of STRO-1-selected cells were injected by direct 
intramyocardial injection into the peri-infarct regions of the ischemic hearts in athymic nude rats who had 
undergone ligation of the left anterior descending coronary artery 2 days earlier. Animals injected with 1 × 
106 STRO-1bright cells (D) demonstrated threefold greater numbers of arterioles at the peri-infarct region 
than animals injected with saline (B; P <0.01). In contrast, animals injected with only 0.2 × 106 STRO-
1bright cells (C), delivered in a total of 1 × 106 unfractionated cultured progeny of STRO-1-selected cells, 
induced only 50% greater numbers of arterioles at the peri-infarct region than saline (P <0.05), indicating 
that STRO-1bright cells have a dose-dependent effect on arteriolar induction in the ischemic heart. 
 
Finally, cardiac function at 2 and 6 weeks was assessed by echocardiography (Figure 1-3) 
and measurement of hemodynamic parameters and correlated with cardiac histology and 
immunohistochemistry. Animals receiving 1×106 STRO-1bright cells demonstrated mean 
improvement in ejection fraction of 50% and 75% at 2 and 6 weeks, respectively, relative to 
baseline values 2 days after LAD ligation. In stark contrast, saline-treated animals showed only 
5% mean improvement in ejection fraction by 6 weeks (P<0.01), and animals treated with 





receiving saline. Injection of 1×106 STRObright cells resulted in similar dramatic improvement in 
fractional shortening (mean improvement of 70% and 90% at 2 and 6 weeks, respectively). 
STRO-1-depleted bone marrow mononuclear cells again had no effect, while modest 
improvement was seen after injection of 0.2×106 STRO-1bright cells. Insertion of a pressure 
transducer into the left ventricle revealed preservation of contractility (dp/dt) and near normal 
left ventricular end diastolic pressures (LVEDP) six weeks after injection of MSCs.  This effect 
was not seen in animals treated with stro-depleted BMMNCs or saline controls. 
 
          
Figure 1-3: STRO-1bright-dependent myocardial neovascularization results in global improvement of 
parameters of myocardial function. Injection of 0.2 × 106 and 1 × 106 STRO-1bright cells resulted in dose-
dependent improvement in ejection fraction (EF) at 6 weeks, as measured by echocardiography 
compared with saline-treated animals (P <0.01) and animals treated with STRO-1-depleted fresh bone 
marrow mononuclear cells (P <0.01). 
Encouraged by these findings in a rodent model, we next sought to examine the efficacy 
of stro-selected MSCs in a physiologically relevant large animal model of ischemic heart disease 
(16).  Allogeneic MSCs were isolated from male crossbreed sheep using a mAb specific for a 
different epitope of the Stro antigen (STRO-3). Forty-six female sheep had coronary ligations to 





MSCs, 225x106 MSCs, 450x106 MSCs or cell medium were injected into the borderzone (BZ) 
myocardium. Echocardiography was performed at 4 and 8 weeks after MI to quantify LV end 
diastolic (LVEDV) and end systolic volumes (LVESV), ejection fraction (EF) and infarct 
expansion. Colored microspheres were used to assess regional blood flow (RBF). CD31 and 
smooth muscle actin (SMA) immunohistochemical staining was performed on infarct and BZ 
specimens to quantify vascular density. 
 In the control group LVEDV and LVESV increased progressively from 56.4 ± 3.3ml and 
35.1 ± 2.4ml at baseline to 102.8 ± 8.0ml and 89.0 ± 7.5ml at 8 weeks after infarction. In the 
25M group LVEDV and LVESV increased significantly less than in the control from 61.8 ± 
3.8ml and 35.0 ± 3.1ml at baseline to 85.0 ± 7.9ml and 65.0 ± 7.4 ml at 8 weeks after infarction. 
The 75M group also demonstrated a significant reduction in remodeling relative control; 
LVEDV and LVESV were 60.4 ± 3.0 ml and 34.0 ± 3.6 ml at baseline and increased to 84.6 ± 
5.4 ml and 64.5 ± 4.1ml at 8 weeks after infarction. LVESV at 8 weeks after infarction was 
significantly reduced relative to control in the 225M group, 74.1 ± 3.5; however, LVEDV was 
not significantly reduced in this group. The extent of remodeling in the 450M group was not 
appreciably improved over control. Serial LV volume data are summarized in Table 1. 
Table 1: Echocardiographic Data  
  Baseline Post Infarct 4wks 8wks 
Diastolic Volume (ml)     
Control (n=10) 56.4 ± 3.3 73.5 ± 3.1† 98.6 ± 7.8†,‡ 102.8 ± 8.0†,‡ 
25x106 Cells (n=6) 61.8 ± 3.8 90.8 ± 3.6*,† 69.5 ± 5.3*,‡ 85.0 ± 7.9*,†,# 
75x106 Cells (n=5) 60.4 ± 3.0 96.7 ± 5.6*,† 82.8 ± 6.4† 84.6 ± 5.4*,† 
225x106 Cells (n=8) 63.0 ± 4.5 84.4 ± 3.4*,† 92.3 ± 5.2§,† 94.0 ± 4.6† 
450x106 Cells (n=6) 63.3 ± 3.1 93.8 ± 4.4*,† 98.3 ± 4.6§,† 98.4 ± 8.0† 
Systolic Volume (ml)     
Control (n=10) 35.1 ± 2.4 53.4 ± 3.4† 84.0 ± 8.1†,‡ 89.0 ± 7.5†,‡ 
25x106 Cells (n=6) 35.0 ± 3.1 59.9 ± 3.1† 52.4 ± 3.1*,†,‡ 65.0 ± 7.4*,† 





225x106 Cells (n=8) 38.9 ± 4.0 54.2 ± 3.1† 72.0 ± 5.6§,†,‡ 74.1 ± 3.5*,†,‡ 
450x106 Cells (n=6) 38.9 ± 2.5 64.0 ± 5.0† 77.9 ± 4.6§,@,† 77.8 ± 8.4† 
Ejection Fraction (%)     
Control (n=10) 37.9 ± 2.0 27.6 ± 3.4† 15.9 ± 1.6†,‡ 13.7 ± 0.9†,‡ 
25x106 Cells (n=6) 43.7 ± 1.7 34.0 ± 2.1† 24.0 ± 1.9*,†,‡ 23.8 ± 3.0*,†,‡ 
75x106 Cells (n=5) 43.3 ± 6.0 35.2 ± 1.9 26.0 ± 2.6*,†,‡ 23.6 ± 2.4*,†,‡ 
225x106 Cells (n=8) 38.6 ± 2.7 35.7 ± 3.2 22.5 ± 2.4*,†,‡ 20.9 ± 2.1*,†,‡ 
450x106 Cells (n=6) 38.5 ± 2.2 31.9 ± 3.4 20.9 ± 1.9t*,† 20.8 ± 3.2*,†  
Values are means ± standard error of the mean; *p<0.05 vs. Control, §p<0.05 vs. 25x106 Cells, 
@p< 0.05 vs. 75x106 Cells, †p<0.05 vs. Baseline, ‡p<0.05 vs Post Infarct,   #p<0.05 vs. 4wk 




 Ejection fraction decreased to 13.7 ± 0.9% at 8 weeks after infarction in the control 
group. EF at 8 weeks after infarction was significantly improved in the 25M, 75M, 225M and 
450M treatment groups with values of 23.8 ± 3.0%, 23.6 ± 2.4%,  20.9 ± 2.1% and 20.8 ± 3.2%, 
respectively. Serial EF data are presented in Table 1. The length of the long axis wall motion 
abnormality or infarct length (IL) immediately after coronary occlusion was similar in the 
control (6.74±0.28cm) and treatment groups (6.73 ± 0.22cm, 25M; 7.46 ± 0.19cm, 75M; 6.41 ± 
0.29cm, 225M; 6.97 ± 0.17cm, 450M) confirming that the infarct size and remodeling stimulus 
were comparable in all groups. Control group animals experienced progressive infarct expansion 
as IL increased to 8.70±0.37cm and 9.20±0.32cm at 4 and 8 weeks after infarction, respectively. 
Infarct expansion was significantly reduced in the 25M, 75M and 225M groups (Table 2). 
Table 2: Infarct Size Measurements 
  Infarct Length (IL) (cm) Infarct size (%) 
  Post Infarct 4wks 8wks (Planimetry) 
Control (n=10) 6.74 ± 0.28 8.70 ± 0.37‡ 9.20 ± 0.32‡,# 24.4 ± 1.4 
25x106 Cells (n=6) 6.73 ± 0.22 7.40 ± 0.33* 7.48 ± 0.33* 23.9 ± 1.9 
75x106 Cells (n=5) 7.46 ± 0.19§ 7.72 ± 0.35 7.88 ± 0.16* 21.4 ± 0.9 
225x106 Cells (n=8) 6.41 ± 0.29@ 7.50 ± 0.23*,‡ 8.23 ± 0.22*,‡,# 23.7 ± 0.8 





Values are means ± standard error of the mean; *p<0.05 vs. Control, §p<0.05 vs. 25x106 Cells, 
@p< 0.05 vs. 75x106 Cells, &p<0.05 vs. 225x106‡p<0.05 vs Post Infarct,   #p<0.05 vs. 4wk 
Follow Up, Analysis by repeat measures ANOVA. (Note: Post Infarct time point is also post 
cell/vehicle injection) 
 
 Both CD31 and SMA staining demonstrated a significantly increased number of 
vessels/hpf in borderzone myocardium of the 25M and 75M groups relative to control.  Similar 
to the histologic findings in earlier rodent studies, these differences were most pronounced with 
SMA staining suggesting that arterioles and small muscular arteries were primarily responsible 
for the increased vascular density in these two groups. Borderzone vascular density was not 
significantly different in either the 225M or 450M groups relative to control. All vascular density 
data are summarized in Figure 1-4.   
 
Figure 1-4: Quantitative assessment of borderzone (BZ) (A, B) and infarct (C, D) vascular density using 
smooth muscle actin (SMA) and CD31 immuno-histochemical staining in control and mesenchymal 
precursor cell (MPC) treated animals 8 weeks after infarction (M=106). *p<0.05 vs Control; † p<0.05 vs 







Regional blood flow data are summarized in Table 3. Infarct regional blood flow was 
0.22±0.04cc/gm/min in the control group. Infarct blood flow was significantly increased in the 
25M group (0.34±0.06cc/gm/min) and 75M group (0.37±0.07cc/gm/min) relative to control. 
This effect on infarct blood flow was not observed in the 225M group (0.20±0.03 cc/gm/min) 
and 450M group (0.23 ± 0.06cc/gm/min).  Collectively these data support the functionality of the 
newly formed vessels seen in tissue sections. 
 
 
Table 3: Microsphere Regional Perfusion Data 
  Infarct BZ Remote 
  (cc/gm/min) (cc/gm/min) (cc/gm/min) 
Control (n=10) 0.22 ± 0.04 0.73 ± 0.11 0.66 ± 0.09 
25x106 Cells (n=6) 0.34 ± 0.06* 0.76 ± 0.06 0.65 ± 0.06 
75x106 Cells (n=5) 0.37 ± 0.07* 0.69 ± 0.08 0.61 ± 0.09 
225x106 Cells (n=8) 0.20 ± 0.03§,@ 0.81 ± 0.15 0.72 ± 0.15 
450x106 Cells (n=6) 0.23 ± 0.06 0.75 ± 0.11 0.63 ± 0.10 
Values are means ± standard error of the mean; *p<0.05 vs. Control, 
§p<0.05 vs. 25x106 Cells, @p< 0.05 vs. 75x106 Cells; Repeat measures 






In the small animal experiments, we have shown that intramyocardial injection of human 
STRO-1bright mesenchymal precursor cells results in dose-dependent induction of arteriogenesis 
and vascular network formation in various tissues, including ischemic myocardium. In the 
mature vascular system, the endothelium is supported by mural cells, with the smallest 
capillaries partially covered by solitary pericytes, and arteries and veins surrounded by single or 
multiple layers of vascular smooth muscle cells. Pericytes coexpress α-SMA and STRO-1 





(13). The perivascular in vivo location of human mesenchymal lineage precursors, together with 
their coexpression of markers of both endothelial and smooth muscle lineage cells and their 
multipotential capabilities, raise the intriguing possibility that mesenchymal lineage precursors 
may be true progenitors of the vascular tree. 
The intimate proximity of human perivascular mesenchymal lineage precursors to 
vascular endothelium suggests that each cell type influences the biology of the other. Migration 
of mesenchymal lineage precursors and formation of a pericyte coating in physical continuity 
with the nascent vascular network is dependent on production of endothelial growth factor (EGF) 
and platelet-derived growth factor-[beta] (PDGF-B) by nascent endothelial tubes (17). 
Conversely, maintenance of vessel integrity, stabilization, and prevention of vessel pruning is 
dependent on pericyte coating of the microvessel. 
A major limitation to successful cellular therapy in animal models of myocardial damage 
has been the inability of the introduced donor cells to survive in their host environment due to 
lack of an appropriate vascular supply. Recent studies have shown that development of thin-
walled capillaries in ischemic myocardium following transplantation of hematopoietic lineage 
endothelial precursors enhances survival of endogenous cardiomyocytes (3,15).  Moreover, 
transplanting cultured cardiomyocytes that incorporate more vascular structures in vivo results in 
significantly greater cell survival and protection against apoptosis (18).   In the present study, we 
showed that implantation of STRO-1bright mesenchymal precursors into the acutely ischemic 
myocardium was accompanied not only by arteriogenesis, but also by sustained improvement in 
both global systolic and global diastolic parameters of cardiac function. While not directly 
examined, these results suggest a direct effect on regeneration of endogenous, mature 





both the functional improvement witnessed and the regeneration of cardiomyocytes may depend 
on paracrine secretion rather than direct cell-to-cell interactions. 
The large animal data provides several additional insights into Stro-bright MSC mediated 
repair.  First, the effect of Stro-selected MSCs is conserved across species and scaled reasonably 
well in going from a small to a large animal model.  Second, a paradoxical dose effect was seen 
in sheep wherein lower doses (25M, 75M) were more effective than higher doses across multiple 
parameters.  This observation calls into question the “more is better” approach and highlights the 
need for careful dose-ranging studies to support clinical application.  In these particular cells, the 
dose effect may be related to the secretory profile of MSCs.  Specifically, cytokines such as 
TNF-α and the interleukins can show beneficial effects within relatively narrow dose ranges with 
ineffective or even detrimental effects seen outside this range.  Finally, in addition to the 
observed arteriogenesis, MSCs exhibited a strong inhibition of remodeling as evidenced by 
preserved LV chamber size and lack of infarct expansion in treated animals.  Future studies of 
the material properties of cell treated infarcts as well as interactions between MSCs and newly 
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CHAPTER 2: Intracardiac In Situ Polymerization of Fibrin-Based Hydrogels Improves 
MPC Engraftment and Function 
 
One key limitation of all existing modalities of cell delivery is the massive cell loss that 
occurs within a very short time and irrespective of cell type or formulation, delivery technique 
and disease state.  Indeed our prior work utilizing MSCs in a liquid suspension demonstrated 
minimal retention and engraftment in both small and large animal models.  Quantitative 
estimates for acute retention vary depending upon route of delivery and cell type but are 
uniformly poor (1,2).  For instance, in an elegant study utilizing radio-labeled bone-marrow 
mononuclear cells (3), only 11 ± 3% of cells remained in the heart just 90 minutes after 
intramyocardial injection. Retention rates for intracoronary (2.6 ± 0.3%) and retrograde venous 
delivery (3.2 ± 1.0%) were even lower.  All three methods were associated with rapid 
redistribution of the cells delivered into the heart to the lungs, liver, spleen, and other organs 
throughout the body. Postulated mechanisms for poor retention include inadvertent intravascular 
delivery to coronary veins and venules, rapid interstitial clearance by lymphatics, and direct 
leakage of cell suspension once the needle is removed.  
In addition, the local environment presents an untenable milieu for freshly implanted 
cells following both acute (inflammation) and chronic (fibrosis) myocardial infarction (4). The 
infarct bed is poorly oxygenated, contains dead and apoptotic cells, and has a progressively 
increasing stiffness, a combination of features that does not support the viability and well being 
of implanted cells. This additional limitation of delivering “naked” cells has prompted research 
towards multiple other modalities for cell delivery – from the use of biomaterials as cell delivery 
vehicles (5) to engineering a contractile cardiac “patch” containing the repair cells (6). 
 Intramyocardial in situ polymerization of polymers in the form of a hydrogel represents 





“conditioning” of the immediate cell environment.  There are a number of biocompatible 
hydrogels, polymerizing in response to chemical, thermal or optical triggers, including fibrin (7), 
alginate (8), and polyethylene glycol-based systems (9).   Fibrin glue is a hydrogel widely used 
in surgery, cell culture and tissue engineering that consists of a two component system. 
Fibrinogen monomers (component A) are dissolved in a liquid carrier such as saline. Exposure of 
fibrinogen monomers to thrombin (component B) results in conversion of fibrinogen to fibrin 
that polymerizes to form a fibrin mesh, by mechanisms similar to those involved in normal 
clotting in vivo. Both autologous and recombinant off-the-shelf fibrin glue preparations are 
available, and have seen extensive use as procoagulants during cardiac and other surgery.  
Fibrinogen and its associated polymerized fibrin mesh also possess a wide range of biological 
activities including but not limited to soluble growth factor binding, endothelial cell recruitment 
and stimulation of fibroblast proliferation (10).   
Results 
 
Given the myriad functions attributed to fibrinogen, we first sought to determine the 
effect of fibrin-based culture on the behavior of Stro-selected MSCs.  First, 1 million fifth 
passage MSCs suspended in saline containing thrombin were mixed with a fibrinogen solution to 
produce hydrogels containing an even distribution of MSCs in a 2% by weight fibrin gel.  An 
equal number of MSCs were cultured using standard monolayer techniques and supernatants 
were collected from both conditions for Luminex array analysis.  Culture in the fibrin hydrogel 
resulted in a significant increase in release of multiple cytokines compared to monolayer culture 
including increased VEGF, IL-6, IL-8, and MCP-1.  In addition, while both monolayer and 





to mimic conditions encountered in an acute infarct resulted in a profound increase in VEGF 
release (1186+/-84 vs. 170+/-2 pg/ml, p<.05, Figure 2-1).   
 
Figure 2-1: Exposure of MSCs to hypoxic culture conditions for 24 hours results in a substantial increase 
in VEGF release compared to culture under normoxic conditions. 
 
Furthermore, RT-PCR array analysis revealed an 18-fold increase in Flk1 (VEGFR2) expression 
and a 6-fold decrease in Flt1 (VEGFR1) expression when MSCs were cultured in fibrin 
hydrogels compared to monolayer.  Given that Flt1 is thought to act as a downregulator of VEGF 
responsiveness while Flk1 transduces the major angiogenic effects of VEGF (reference), the 
overall effect of fibrin-based culture on MSCs both increased the amount of VEGF produced as 
well as altered their responsiveness to VEGF setting up a possible autocrine amplification of 
VEGF-mediated angiogenesis. 
 To confirm the hypothesis that in situ polymerization of MSCs delivered in fibrin would 
result in improved short term retention compared to delivery in saline, 2.5x105 MSCs were 
delivered in fibrin glue or saline by intramyocardial injection forty-eight hours after LAD 





the human beta-globin gene was conducted to quantify intracardiac retention.  Delivery in fibrin 
was associated with an 8-fold increase in recovered MSCs (107,000+/-30,000 vs. 14,000+/-
24,000, p<.05, Figure 2-2).  In an effort to demonstrate that xenogeneic immune responses 
played no role in immediate cell loss, a cohort of animals was sublethally gamma-irradiated prior 
to infarction and cell delivery.  Quantification of retention in these animals revealed no 
difference between irradiated and non-irradiated controls. 
 
Figure 2-2: 2.5x105 MSCs were delivered by intramyocardial injection 48 hours after LAD ligation.  48 
hours after cell delivery hearts were explanted and MPCs quantified By PCR using human-specific 
probes for beta-globin.  The PBS and radiated groups received MSCs suspended in saline.  The FGLU 
group received the same number of cells suspended in a 1:5 dilution of thrombin and codelivered with a 





 Next we sought to explore the in vivo behavior of MSCs delivered in fibrin as well as the 
effect of increased cytokine production and improved retention on previously demonstrated 
repair mechanisms.  To accomplish this, nude rats underwent LAD-ligation followed by injection 





Histologic assessment two weeks after MSC delivery revealed an enhancement of multiple repair 
mechanisms by fibrin-based delivery.  Arteriogenesis, quantified by SMA+ vessels /high power 
field, was significantly more robust in the MSC-fibrin group compared to MSCs delivered in 
saline and acellular fibrin glue and saline controls (Figure 2-3).   
 
Figure 2-3: Injection of 1x106 MSCs 48 hours after infarct as a fibrin hydrogel resulted in a significant 
increase in arteriogenesis compared to saline based delivery and acellular controls.  Histology revealed 
11.4 +/- 2.1 SMA+ vessels/hpf in the hydrogel group compared to 7.1 +/- 0.8 vessels/hpf in the PBS 
group (p<.05).  Representative images of the borderzone (top) show SMA+ vessels with Ki67+ 
endothelial and smooth muscle components (bottom) indicating ongoing arteriogenesis. 
Similarly, the use of a fibrin vehicle resulted in greater cell cycling of native cardiomyocytes 






Figure 2-4: Intramyocardial injection of MSCs resulted in an increase of endogenous myocyte cell cycling 
as evidenced by troponin+/Ki67+ myocytes (right).  Delivery of MPCs in a fibrin hydrogel resulted in a 
significant increase in the number of cycling myocytes (4.4 +/- 0.7 vs. 1.5 +/- 1.1 cycling myocytes/hpf, 
p<.05). 
 
Of note, human mitochondrial staining revealed nests of surviving MSCs at two weeks much 
more frequently in fibrin-treated animals.  Furthermore, these nests were seen in perivascular 
locations (Figure 2-5) but did not show any evidence for differentiation of MSCs into either 







Figure 2-5: Human-specific mitochondrial stain labeled the cytoplasm of surviving MPCs brown.  The 
MPCs were frequently found in a perivascular location but did not contribute to the mural elements of 
blood vessels or exhibit evidence of cardiomyocyte differentiation. 
 
 Finally, we quantified the functional effect of improved retention and arteriogenesis by 
conducting echocardiography at baseline prior to cell delivery, three weeks, and six weeks after 
MSC injection.  Fractional shortening and area change were significantly improved compared to 
baseline in animals receiving the MSC-hydrogel delivery system whereas those receiving MSCs 
in saline demonstrated a trend towards improvement in these parameters that did not reach 
statistical significance.  Acellular fibrin treated animals showed no change in several functional 
parameters and animals receiving saline vehicle injection demonstrated a trend toward continued 
loss of function (Figure2-6).  
 
Figure 2-6: Echocardiography at Post-infarct Baseline (blue), 3 weeks post treatment (red) and 6 weeks 
post-treatment demonstrated an improvement in fractional shortening in animals treated with MPCs that 












 Intracardiac in situ polymerization of fibrin based hydrogels offers several advantages 
over cell delivery in liquid suspension.  First, the rapidly forming fibrin mesh provides a physical 
barrier to cell egress through lymphatics and the injection channel created by the delivery needle.  
In addition, fibrin contains binding sites for several cell receptors such as integrins that may 
further anchor delivered cells at the injection site (11).  Polymerized fibrin also serves as an 
effective growth factor trap that may increase the concentration of both endogenously produced 
and MSC-released cytokines such as VEGF and FGF that may further enhance the angiogenic 
potential of injected cells (10,12). 
 Despite the large increase in local retention provided by fibrin polymerization,   minimal 
MSC differentiation was observed.  Instead, as was seen in prior animal studies, the surviving 
cells recapitulated their native niche and assumed ‘pericyte-like’ locations in the proximity of 
newly formed vessels.  This observation contradicts the notion that the lack of cardiomyocyte 
differentiation seen with bone-marrow derived cell therapy to date is solely due to poor retention.  
Instead, it is likely that ischemic myocardium lacks the signals necessary to guide differentiation 
ard/or the cells themselves may lack the capacity altogether (13).  Nevertheless, it is clear that 
the use of hydrogels as delivery vehicles greatly increases the local retention and activity of 
delivered cells.   
 Hydrogel-based approaches to cell delivery are not without drawbacks.  The preparations 
tend to be complex, requiring combination of multiple components in addition to the intended 
cells.   Furthermore, mixture of these components often initiates polymerization leading to a 
solution with changing viscoelastic properties that may further complicate delivery.  Control 





also greatly increases the time needed to prepare each injection compared to saline or other 
liquid suspensions.  Also the risk of intravascular injection of a prothrombotic compound exists 
and could potentially lead to embolic adverse events.  Despite these drawbacks, the use of in situ 
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CHAPTER 3: Optimization of Fibrin Hydrogel Properties for Catheter Compatability 
 
 Current clinical cardiac cell therapy protocols are being performed by both surgical and 
catheter based (percutanous) methods. Catheter-based cell delivery has several advantages over 
direct surgical injection: 1) lower procedure risk, 2) high potential for integration into clinical 
practice, and 3) more suitability for repeat applications compared to surgery (1).  For these 
reasons, the majority of current cardiac cell therapy trials employ a percutaneous delivery 
method the most common type of which is endoventricular or transendocardial injection.   
However, the use of intramyocardial injection catheters also imposes significant design 
constraints on a cell:hydrogel preparation (Figure 3-1).  First, the long internal lumen of the 
catheter imposes a high resistance to flow that in turn limits the maximum viscosity of the 
injectate.  Second, because current catheters employ a single injection lumen, all components 
must be mixed prior to injection, resulting in a time-dependant increase in viscosity of most cell-
hydrogel suspensions. A successful formulation must therefore polymerize quickly enough to 
improve cell retention, yet slowly enough to allow adequate time for injection site selection, 
catheter positioning, and delivery.   
 In this chapter we first assess the utility of several commercially available percutaneous 
catheters using standards of solutions with known viscosity to determine a working limit for this 
parameter.  Next we characterize the polymerization kinetics of different fibrin glue solutions to 
define the ranges of parameters compatible with catheter delivery. We then demonstrate the in 
vitro and in vivo effectiveness of this preparation, and its ability to increase cell retention and 
prevent redistribution of delivered product in an animal model of myocardial infarction while 






Figure 3-1.  Catheter-based delivery of actively polymerizing compounds is limited by increasing 
resistance to flow over time and requires a balance between overly rapid (clogged catheter) and overly 
slow (loss of cell product) kinetics. 
 
Results 
Given the importance of hydrogel flow properties for catheter-based delivery of cell-
hydrogel suspensions, we first specified the range of hydrogel viscosity that is compatible with 
the use of a catheter. Hydrogel preparations were formed by utilizing dextran-based standards, to 
obtain a series of solutions with a gradually increasing viscosity.  Four different catheter types 
with a wide range of path lengths (115-177.5 cm) and inner diameters (0.19-0.43 mm) were used 
in these rheological studies.  Table 4 summarizes these studies.  Dextran solutions with 
concentrations less than 5% w/v (viscosity of ≤9.39 cP) were easily passed through all four 
catheters. All catheters except for the one with the longest and most narrow lumen (catheter D) 
handled the 10% Dextran solution (viscosity of 30.8cP) with ease. Injection of 20% Dextran 
solutions  







(viscosity of 121 cP) was possible through catheters A, B, and C, but significantly more force 
was required compared to less viscous solutions to produce forward flow.  Only the catheter with 
the shortest path length (catheter C) was able to pass 25% Dextran solutions (231 cP).  From 
these tests we estimated an operational viscosity upper limit in the 150 – 200 cP range.   
Next we analyzed the starting viscosity of fibrinogen suspended in saline prior to addition 
of thrombin and initiation of polymerization (Figure 3-2a).  Fibrinogen solutions demonstrated a 
nonlinear increase in viscosity with increasing fibrinogen concentration  however all solutions 
tested were well under the established upper limit of 200 cP.  Above fibrinogen concentrations of 
15%, visible clumping occurred and could only be overcome by elevating the temperature of the 
mixture well above body temperature.  Having now established acceptable starting 
concentrations of fibrinogen (<15% w/v) we characterized the time-dependant changes in 
viscosity associated with addition of thrombin and polymerization of fibrin monomers (Figure 3-
2b). Early testing with higher fibrinogen concentrations (>10% w/v) was associated with rapid 
polymerization that was incompatible with percutaneous delivery.  In contrast, by decreasing the 
starting concentrations of fibrinogen to 5 % and of thrombin to 20 U/ml, injection windows in 





could be easily cleared from catheter C by manual flushing with saline enabling re-use of the 
catheter with freshly mixed fibrin glue. 
 
Figure 3-2. a) Fibrinogen solutions show a nonlinear increase in viscosity with increasing weight 
percentage.  b) By maintaining fibrinogen weight percentages below 5% w/v and thrombin concentrations 
under 20U/ml, polymerization rates can be controlled to allow adequate time for percutaneous delivery.  
The dotted line indicates the operational upper viscosity limit of 200 cP. 
 
To characterize the biocompatibility of fibrin glue, we encapsulated fourth passage 
mesenchymal stem cells in 2% w/v gels polymerized with 20U/ml of thrombin.  This preparation 
demonstrated excellent long term viability (Figure 3-3a) and normal morphology (Figure 3-3b) 





hours, hydrogels were lyophilized for scanning electron microscopy (SEM) which demonstrated 
pore sizes in the 20-40 mm range (Figure 3-3c) and a somewhat homogenous architecture 
(Figure 3-3d).  RT-PCR analysis of several hMSC markers including alpha smooth-muscle actin 
and connexin-43 showed no significant change in expression after 72 hours of culture in fibrin 
glue (data not shown). 
 
Figure 3-3. a) MSCs cultured in fibrin gels maintained excellent viability over 72 hours of culture b) Live-
dead stain of MSCs 72 hours after culture in a fibrin gel (living cells stain green, dead cells stain red). 
c+d) SEM of a 2% (w/v) fibrinogen gel polymerized with 20U/ml of thrombin showing a heterogenous 
structure with pore sizes in the 20-40 micrometer range. 
Having established acceptable parameters for percutaneous application, we tested the in 
vivo effectiveness of intracardiac polymerization of fibrin glue in a rat model of acute myocardial 
infarction.  Early attempts to inject hydrogel via a 23G needle resulted in excessive bleeding. 
After the needle size was reduced to 26G 5/8”, successful delivery of a 2% w/v 





injection of this preparation resulted in a visible blanching of the anterior wall with no 
appreciable loss of injectate from the injection site (Figure 3-4a).  Ten days post-injection the 
anterior wall demonstrated visible retention of polymerized fibrin grossly (Figure 3-4b,c) and 
histologically (Figure 3-4d). 
 
Figure 3-4.  a) Intramyocardial delivery of MSCs suspended in fibrin glue results in gross retention of 
hydrogel (b) and noticeable infarct thickening (c) ten days after infarction and injection.  d) Trichrome 
staining of a left ventricular cross section demonstrates intramural presence of injectate. 
To quantify the effect of in situ polymerization of fibrin glue on cell retention and redistribution, 
we next suspended 500,000 iridium-labeled hMSCs in either saline or fibrin glue (2% w/v 
fibrinogen, 20U/ml thrombin) and delivered them into acutely infarcted nude rats via 2 separate 
150 µL injections.  Ninety minutes after cell delivery, the rats were sacrificed and the hearts and 
remote organs procured for quantification of retained cells (Figure 3-5e).  There was no 





(3.31 ± 1.39x105 vs. 3.41 ± 1.00x105, fibrin glue vs. saline).  Delivery of hMSCs in fibrin glue 
was associated with a substantial increase in local cardiac retention (39.7% ± 7.0% vs. 22.6% ± 
3.5 of recovered cells, p<0.05) as well as a significant reduction in redistribution to the liver 
(21.7 ± 7.9% vs. 41.7 ± 0.4%, p<0.05) and kidney (0.3 ± 0.3% vs. 8.9 ± 8.8%, p<0.05).  
Interestingly, redistribution of hMSCs to the lungs was not statistically different for the two 
methods (38.3 ± 14.6% vs 23.9 ± 9.3%). 
 
Figure 3-5. Quantification of iridium-labeled MSCs confirms a significant increase in local cardiac 
retention as well as prevention of end organ redistribution when MSCs are delivered in fibrin glue (black 
bars) compared to saline (white bars). 
Discussion 
 
 Heart failure following acute and chronic myocardial infarction remains a therapeutic 
challenge with gradual progression of disease and functional decline leading to death being the 
most common outcome. Various modalities of cell delivery have gained a lot of attention in 
recent years. While early clinical trial results were very promising, larger randomized trials have 
produced conflicting data (2-4) sometimes with similar cell types showing sometimes positive 





delivered cells may be due to differences in cell processing, delivery methods, and timing of 
administration, such that poor cell retention and engraftment remain a central problem common 
to all cell types and routes of administration. 
 In this study, we have demonstrated that by controlling the composition of fibrinogen and 
thrombin components, a fibrin-based hydrogel can be prepared that is compatible with current 
percutaneous injection catheters.  This hydrogel can be delivered under clinically relevant 
conditions (point of care component mixing, 10 minute injection window) and greatly enhances 
local retention of injected cells in the heart as well as prevents their redistribution to distance 
organs.  Furthermore, the system and parameters developed here are applicable to all cell types 
and may represent an enabling technology capable of improving current cell delivery techniques. 
 While some of the currently available catheters were suitable for cell-hydrogel delivery, a 
number of avenues for design improvement exist.  First, given that the device with shortest path 
length and largest internal luminal diameter performed best, increasing the inner diameter even 
slightly may result in broadening the injection window by raising the upper limit of passable 
viscosity.  Second, a double-lumen system that keeps the fibrinogen and thrombin components 
isolated until they reached the target tissue would potentially relieve the timing constraints 
associated with intra-catheter polymerization altogether. 
 As this was only an initial pilot study, more robust functional studies should be 
undertaken to determine if the retention and distribution benefit demonstrated here results in 
greater functional recovery.  The technique should also be applied to other cell types to confirm 
its broader potential.  Alternative hydrogel systems are also available allowing for the possibility 





through growth factor tethering or backbone modification may result in even greater benefit and 
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Given the limited capacity of the heart to repair itself through endogenous mechanisms 
(1), cell-based therapy has emerged as a viable candidate for both vascular network (2) and 
myocyte regeneration (3). Several cell sources and delivery methods are rapidly progressing 
through clinical trials, particularly in the setting of end-stage heart failure where a lack of 
effective medical therapies and the shortage of donor organs for transplant lead to more than 
500,000 deaths per year in the United States alone (4). Most current clinical protocols utilize a 
liquid suspension of cells that allows for relative ease of administration but introduces severe 
limitations: poor short-term retention (5), limited long term survival (6), and low rates of 
engraftment (7) and differentiation (8). 
Pioneering work by the Badylak and Taylor teams demonstrated that a number of tissues 
can be decellularized and implanted either as acellular scaffolds (9) or cell-seeded constructs 
(10) in a variety of anatomic locations (11,12). For cardiac applications, the use of decellularized 
myocardium as a delivery vehicle offers several advantages over the delivery of “naked” cells 
suspended in saline or culture medium. First, the scaffold architecture can impose long-range 
order for seeded cells (13). Second, signaling involving matrix components and cell surface 
receptors can restore a more physiologic balance between the cells and their microenvironment 
and provide cues to guide differentiation (14). Finally, creative strategies for pre-implant seeding 








Here we introduce a novel cell delivery platform that combines the use of a fully 
biological composite scaffold with biochemical preconditioning of immunoselected 
mesenchymal precursor cells (MPC), and show that this platform can greatly enhance vascular 
network formation in an animal model of myocardial ischemia (Fig. 4-1).  
 
Figure 4-1: Composite scaffolds are assembled from thin sheets of decellularized human myocardium 
and human mesenchymal progenitor cells (MPCs) encapsulated in fibrin hydrogel, and cultured in vitro, 
with or without TGF-β conditioning before implantation into nude rat models of acute ischemia, chronic 
ischemia, or normal myocardium. Four weeks later, the heart function was evaluated by 






The composite scaffold was constructed as a sandwich of a cell-dense fibrin layer 
between two thin sheets of decellularized human myocardium. In the composite, decellularized 
native tissue provided a substrate with excellent mechanical properties that could retain sutures, 
yet be pliable enough to be molded to any surface, while the fibrin gel enabled retention of cells 
within a spatially confined area (Fig 4-2a,b). The average thickness of decellularized sheets (Fig 
4-3 a-b) was 300 ± 50 µm, resulting in the overall construct thickness of 600-700 µm. The 
optimal decellularization protocol (lysis for 2 hrs, detergent for 6 hrs, DNAse/RNase treatment 












Figure 4-2: (a) Macroscopic view of a decellularized scaffold. (b) Composite scaffold constructed by 
placing a fibrin layer seeded with cells between two layers of decellularized tissue seded with cells. (c-d) 
Parallel blade array used for sectioning explanted hearts. (e-j) Scanning electron micrographs of 
decellularized scaffolds: scaffolds obtained from circumferential (e, 796X) and apex to base (f, 986X) 
sections, image of vascular basement membrane (g, 351X) and scaffolds obtained from circumferential 
sections (h, 400X; I, 1000X; j, 2500X). (k) Histogram documenting average pore diameters in 
decellularized scaffolds. (l) Uniaxial tensile testing reveals similar mechanical properties of native and 
decellularized tissue; tensile moduli at 20% strain are shown. (m) Schematic presentation of the heart, 
indicating the three axes (r, θ, z) and directions for sectioning (apex-to-base, circumferential, radial) 
scaffolds. (n) Short axis of myocytes seen in circumferentially sectioned sheets of myocardium. (o-p) 
Collagen IV immunohistochemistry of circumferentially cut native (o) and decellularized tissue (p). Scale 
bar: 250 µm. 
 
Cardiomyocyte orientation within the ventricular wall is both highly defined and highly 
anisotropic (16). Consequently, the architectures of decellularize matrix differed greatly 
depending on the direction of sectioning (Fig. 4-2 e-n). Scanning electron microscopy revealed 
low porosity and closed pores in apex to base (Fig 4-2e) and radial (Fig 4-2f) sections, due to the 
lack of cells and blood vessels oriented perpendicular to the sectioning plane. In contrast, 





number of myocytes presenting their short axis in the sectioning plane. Only circumferential 
sections were thus used for cell seeding. The majority of myocyte-derived pores were between 
11 and 25 µm in diameter, with a mean diameter of 16.7 ± 3.5 µm (Fig 4-2k). Also of note, large 
smooth channels (Fig 4-2g) corresponding to intramyocardial arterioles, which could facilitate 
oxygen transport and cell infiltration and possibly serve as precursors for new blood vessels, 
were most often seen in circumferential sections.  
In the decellularized matrix, type I collagen backbone, collagen IV (Fig 4-2o-p), laminin, 
and vitronectin (Fig 4-3c-f) maintained their presence and normal distribution.  Specifically, 
laminin and collagen IV localized to the myocyte pores and coronary vessel basement 
membranes, and vitronectin localized to blood vessels and areas of fibrosis. However, 
decellularization consistently removed fibronectin (Fig 4-3g-h). In addition to the preservation of 
the appropriate matrix components and fiber orientation, decellularized myocardial sheets 
maintained physical properties similar to those of relaxed native tissue, measured by uniaxial 
tensile stretch. Tangential moduli of native and decellularized myocardial sheets measured in 
cardioplegic solution were, respectively, 272.9 ± 15 kPa vs. 224.0 ± 37 kPa for circumferential 






Figure 4-3: (a) Scanning electron micrograph of circumferentially cut decellularized myocardium, with 
uniform porosity following the removal of myocytes, and vessel cross sections, 100x. (b) DNA 
quantification of decellularized tissue following several variations of lysis/detergent/DNase treatment, 
compared to native tissue. (c-h) Immunohistochemistry of matrix components in circumferential sections 
of native (c,e,g) and decellularized (d,f,h) tissue, using antibodies for laminin, Vitronectin and Fibronectin 
(left to right). Scale bar: 250 µm. 
 
 
Mesenchymal stem cells (MSCs) represent less than 0.01% of the bone marrow stromal 
compartment. Unlike CD34+ hematopoietic cells, MSCs are multipotential and can differentiate 
into bone, fat, cartilage, and blood vessel cells (17, 18). Immunoselection of MSCs prior to 
expansion using STRO-3 leads to a highly uniform fraction of cells termed here mesenchymal 
progenitor cells (MPCs) (19). To test for variability in genotype and phenotype that may result 
from long-term culture, we characterized the genotypic stability of MPCs at serial passages, and 





Second passage MPCs demonstrated high levels of mRNA for several developmentally 
relevant receptors including BMPR 1 and 2, FGR1, and Fzd 1 and 2 (Fig. 4-4b), and showed 
remarkable stability in expression between the second and fourth passage.  Expression of 
myogenic lineage markers was similarly stable with the exception of Islet1 which showed some 
expression at second passage but no expression at fourth passage.  Of note, the cardiac specific 
markers Nkx2.5 and GATA4 were not expressed at second or fourth passage, while Mef2C, 
GATA6, and Tbx5 were expressed slightly less at fourth than at second passage. 
In contrast to myogenic and lineage markers, significant upregulation of vascular 
cytokines, receptors, and structural proteins occurred between the second and fifth passage. 
Specifically, mRNA for angiogenic factors (SDF-1, angiopoietin, endothelin) was upregulated 
2.1, 2.6, and 11.3 fold, respectively. In addition, the expression of endothelin receptors A and 
Flt1 increased 5.7 and 2.0 fold, respectively, between second and fifth passage. Finally, several 
vascular smooth muscle markers were upregulated between second and fifth passage, including 
alpha smooth muscle actin (3.7 fold), myocardin (7.5 fold), and connexin 43 (2.5 fold).  
Collectively, these data were used to select fifth passage MPCs for use in subsequent studies, 







Figure 4-4: Characterization of the genotypic and phenotypic profiles of immunoselected human 
mesenchymal progenitor cells (MPCs). (a) Schematic of STRO-3 immunoselection of MPCs from bone 
marrow aspirates. Cells were obtained from Angioblast Systems, through an active Materials Transfer 
Agreement, following STRO-3 isolation, and expanded up to passage 5. (b) RT-PCR of MPCs to analyze 
genotypic profile for developmental markers (top left, passages 2-4), cardiac markers (top right, passages 
2-4) and vasculogenic markers (bottom, passages 2-5). FC designates fold change for osteochondral 
markers (c-f) and vasculogenic markers (g-h), in cells cultured with TGF-b supplementation. Data are 
shown as Ave ± S.E.M. 
 
Transforming growth factor beta (TGF-β) is a cytokine that exerts a wide range of 
disparate biologic effects including proliferation, apoptosis, migration, and differentiation. 
Additionally, TGF-β has been implicated in the maintenance of vascular homeostasis, 
angiogenesis, and vascular morphogenesis (20), with affinity for multiple members of the TGF-β 





TGF-β supplementation on the vasculogenic and myogenic profiles of MPCs cultured in vitro. 
Consistent with a previous report (22), intermediate (1.0 ng/ml) and high (10.0 ng/ml) doses of 
TGF-β resulted in significant upregulation of a number of osteochondral genes including 
osteopontin, osterix, aggrecan, and type X collagen (Fig 4-4c-f).  In contrast, low dose 
(0.1ng/ml) of TGF-β was associated with a decrease in osteopontin and aggrecan mRNA, no 
change in osterix or type X collagen message, and an increase in Flt-1 and VCAM expression 
(Fig 4-4g-h). 
The regenerative capacity of MPCs in composite scaffolds was evaluated in a nude rat 
model of acute and chronic myocardial ischemia. Four weeks post-implant, all three groups 
demonstrated complete physical integration to the underlying myocardium. In the acute model, 
TGF-β and MPCs markedly enhanced angiogenesis and arteriogenesis of the infarct bed, as 
evidenced by the increased size and frequency of blood vessels positive for factor VIII and SMA, 
respectively. The number of factor VIII positive cells per view field, an indicator of 
angiogenesis, was 21.3 ± 5.1 for TGF-β + MPCs + scaffold group, 14.7 ± 5.4 for MPCs + 
scaffold group, and 9.8 ± 4.4 for acellular scaffolds (p<0.05, Fig. 4-5 a-d). The number of SMA 
positive cells per view field, an indicator of arteriogenesis, was 10.5 ± 2.4 for TGF-β + MPCs + 
scaffold group, 7.2 ± 3.4 for MPCs + scaffold group, and 3.5 ± 2.0 for acellular scaffolds 
(p<0.05, Fig. 4-5 e-h). 
Significant MPC engraftment occurred within the infarct bed, by the cells migrating from the 
patch into the infarct bed but – importantly - not into the healthy tissue. All three layers of the 
patch were re-populated by the cells of rat origin. TGF-β supplementation significantly increased 
the number of human MPCs within the infarct bed (Fig 4-5i, 6.5 ± 5.2 vs. 0.6 ± 0.7 MPCs per 






Figure 4-5: Implantation of the composite constructs in nude rat models of acute and chronic 
cardiac ischemia. (a-k) Acute infarction model. Quantification and representative images at 4 weeks 
post-implant, of Factor VIII+ (a-d) vessels, SMA+ vessels (e-h), and presence of human MPCs (i-k) for 
each of the composite scaffold groups, in an acute myocardial ischemia model. (l-p) Acute vs chronic 
infarction model. Quantification of MPCs in acute ischemia, chronic ischemia and noninfarcted 
myocardium models, following implantation of TGF-b conditioned composite scaffold. (m-p) 
representative images of human MPC presence in explanted hearts, 4-weeks post implantation of TGF-b 
conditioned scaffold. (q) SDF-1 RT-PCR of MPCs (passage 5) conditioned with TGF-b, shown as fold 
change in SDF-1 expression relative to baseline (in cells not conditioned with TGF-b ). (r) SDF-1 ELISA of 
supernatants from Passage 5 MPCs following culture with or without TGF-b and with or without hypoxia, 
and Western blot demonstrating SDF-1 protein expression (s). (t) Matrigel assay of coronary endothelium 
with (top) or without (bottom) SDF-1 supplementation, 2x magnification. Scale bars: 250 µm. Data are 





MPCs identified within the patch (1.2 ± 1.9 vs. 2.2 ± 2.7 MPCs per view field, p = 0.11) 
suggesting greater mobilization of MPCs from TGF-β supplemented scaffolds. Human MPCs 
were often positioned in close proximity to endogenous vessels (Fig 4-5j-k) but did not appear to 
contribute to either endothelial or intramural components, instead occupying a perivascular 
position. No evidence for myogenesis within the infarct bed or scaffold was seen in any group. 
MPC density in the infarct bed (Fig 4-5l) was markedly and significantly lower in the 
setting of chronic than acute infarction (3.6 ± 2.5 vs. 6.5 ± 5.2 MPCs per view field, respectively, 
p<0.05, Fig 4-5 m-n). Virtually no migration of MPCs into uninfarcted myocardium was 
observed. Consistent with the observed differences between the acute and chronic model, regions 
of inflammation such as chest wall adhesions (Fig 4-5o) or microinfarctions caused by implant 
sutures (Fig 4-5p) in otherwise uninfarcted hearts served as powerful stimuli for MPC migration. 
SDF-1 is a cytokine that is transiently released by acutely ischemic tissues (24), resulting 
in stimulation of angiogenesis, suppression of apoptosis, and homing of progenitor cells derived 
from bone marrow (24,25). RT-PCR analysis of 5th passage MPCs demonstrated strong 
expression of SDF-1 message and a dose-dependant increase with TGF-β supplementation (Fig 
4-5q), accompanied by increased SDF-1 protein expression (Fig 4-5s). ELISA of supernatants 
(Fig. 4-5r) revealed constitutive SDF-1 release by MPCs that was further enhanced by TGF-β 
supplementation. MPC culture under hypoxic conditions was associated with the most profound 
release of SDF-1. Addition of exogenous SDF-1 to coronary endothelium cultured on Matrigel 
enhanced and stabilized endothelial network formation at all time points (Fig. 4-5t). Co-culture 
of MPCs at multiple doses did not have a stabilizing effect.  
To explore the functional consequences of hybrid scaffold implantation, we performed 





Baseline analysis demonstrated an increased left ventricular (LV) diastolic and systolic diameter 
(LVDd and LVDs) and area (LVDA and LVSA), and decreased fractional shortening (FS) and 
area change (FAC) (Fig 4-6b-g) that are normally occurring after infarction. Animals were then 
randomized to receive either no treatment (n=15), intramyocardial implantation of TGF-β 
conditioned MPCs (n=15), or TGF-β conditioned MPCs delivered via a composite scaffold 
(n=15) seven days after LAD ligation (Fig 4-6a).  
Four weeks later, follow up echocardiography in surviving animals indicated further 
deterioration in untreated rats.  In particular, LVDd (Fig 4-6b), LVDA (Fig 4-6c), LVDs (Fig4-
6d) and LVSA (Fig 4-6e) continued to increase while FS (Fig 4-6f) and FAC (Fig 4-6g) declined 
further, indicating significant left ventricular dilation and further loss of contractility. TGF-β 
conditioned MPCs delivered by intramyocardial injection or embedded in a hybrid scaffold had 
no effect on diastolic dimensions compared to untreated animals (Fig 4-6b,c). However, while 
intramyocardial injection of MPCs attenuated the increase in systolic dimensions (Fig 4-6d,e) 
and preserved post-infarction FS and FAC (Fig 4-6f,g), only the animals treated with the hybrid 
scaffold demonstrated statistically significant preservation of systolic area (Fig 4-6e) and 







Figure 4-6.  Changes in left ventricular function after hybrid scaffold delivery. Baseline (n=45) 
indicates pooled values measured three days after myocardial infarction in rats that subsequently 
received intramyocardial injection of MPCs (n=15), patch (hybrid construct) implantation (n=15), or 
received no intervention (n=15). These rats were evaluated after an additional four weeks.  Diastolic 
diameter (b) and area (c) showed little difference between groups whereas systolic diameter (d) and area 
(e) were preserved in MPC injected and patch implanted groups.  Fractional shortening (f) and area 
change (g) continued to decline in untreated controls, and were well preserved by MPC injection and 
slightly (but not significantly) improved by patch implantation. 
 
Discussion 
The technology for cardiovascular cell therapy we describe is applicable to any cell type, 
and could help address the limitations associated with the current clinical paradigm of “naked” 
cell delivery. By suspending the cells in a fibrinogen solution and utilizing thrombin for in situ 
polymerization, we greatly increased the number of cells retained in the scaffold during culture 
and in the infarct bed, following implantation. Interestingly, though initially delivered as the 
middle layer of the patch, MPCs were found in abundance in the infarct bed but very rarely 
within any portion of the scaffold four weeks after implantation. 
Control over cell retention enabled new insights into the regenerative potential of MPCs 
in the infarct bed. Although MPCs expressed some myogenic genes early in culture, their overall 





express the smooth muscle markers (α-SMA, Cx-43, and endothelin receptor A), and the 
endothelial-associated markers (VCAM and Flt1), yet lack smooth muscle myosin heavy chain 
and Tie1. This mixed vascular profile can be further augmented by serial passage and growth 
factor supplementation, as was seen with a low dose of TGF-β.  
Notably, despite a cardiac-like environment, there was no evidence of MPC 
differentiation into cardiomyocytes either in the patch or the native myocardium. In fact, we saw 
no direct evidence of differentiation into either vascular structures or myocytes, a finding 
consistent with outcomes described for MSC-seeded engineered blood vessels (26). Rather, 
MPCs were found clustered in a perivascular location similar to the “niche” they occupy in bone 
marrow (27).  Further, the Matrigel assays confirm that secreted SDF-1 and not MPC-endothelial 
contact is the driving force behind stabilization of vascular networks, as co-culture with multiple 
MPC/endothelium ratios showed no benefit. These observations further support the notion that 
paracrine factors and upregulation of endogenous neovascularization are the primary 
mechanisms of repair seen with bone-marrow derived cells (28), and that the differentiation of 
bone marrow derived stem cells into cardiomyocytes is unlikely to occur in vivo (29).   
Constitutive expression and release of SDF-1 by MPCs suggest a possible mechanism for 
the observed effects. Given that both TGF-β and hypoxia upregulate production and release of 
SDF-1, it is likely that the SDF-1/CXCR4 axis plays a key role in the differential responses seen 
in normal, chronically infarcted, and acutely ischemic myocardium. Normal myocardium is not 
expected to produce a gradient of SDF-1, consistent with the lack of cell migration in uninfarcted 
animals. Inflammation must also serve as a key attractant for MPCs, given their preferential 
migration to thoracic adhesions or implantation sutures. MPC migration into chronic infarcts 





enhanced by constitutively released SDF-1 once the MPCs have entered the infarct bed. 
Nonetheless, acute ischemia was a much more potent attractant for MPCs, supporting the use of 
local cell delivery in protocols targeting myocardial ischemia and heart failure. 
In order to evaluate the added functional benefit of hybrid patch delivery, we implanted 
bilayer patches with direct apposition of the MPC-dense fibrin layer to the infarct bed.  
Interestingly, the echocardiography results mirror those achieved by Eschenhagen’s group (30) 
despite the utilization of different conditioning regimes (mechanical vs. biologic) and cell 
sources (neonatal myocytes vs. MPCs). Specifically, both therapies were shown to preserve the 
functional state of the myocardium at the time of intervention and attenuate remodeling rather 
than return the ventricle to its normal baseline.  In light of this, current cell therapy trials may 
find preservation of chamber geometry and inhibition of deterioration a more realistic endpoint 
than functional improvements. These findings also support the use of cell therapy as a preventive 
measure in early heart failure rather than as a “last resort” treatment for end-stage ventricles 
where little is left to salvage.   
In a broader sense, our approach can be considered an adaptable modular platform. All 
components (cells, scaffold, hydrogel, growth factor) can be tailored to the clinical indication.  
For instance, myogenesis may be achieved by combining an embryonic (or iPS) cell source with 
a hyaluronan-based hydrogel (31). Alternatively, the scaffold could be used as a vehicle to 
deliver microsphere-encapsulated growth factors for sustained release. Ultimately, we envision 
this system as a possible point of care approach, with components produced and assembled at the 
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Cardiovascular cell therapy is rapidly progressing through phase II and III clinical trials 
utilizing a wide range of cell types and delivery methods.  Due to regulatory restrictions, all of 
the current formulations employ "naked" cell delivery through direct intramyocardial injection, 
systemic intravenous, or intracoronary infusion.  The experiments contained in this thesis utilized 
mesenchymal stem cells and demonstrated some of the shortcomings associated with current 
delivery practices.  As these and other cell types achieve regulatory approval, attention will 
undoubtedly turn towards next generation formulations and delivery methods.  This thesis has 
explored two such approaches, namely in situ polymerization of hydrogels and composite 
scaffold delivery.  The former represents a logical next step for any clinically applicable cell type 
given that the individual components can be chosen from already approved starting materials 
with known safety profiles.  The hybrid scaffold approach described in this adds several layers of 
regulatory complexity that will likely preclude its clinical application for some time.  However, 
as attention shifts from simple delivery and limited angiogenesis to complex myogenic 
preparations, approaches such as this will likely become common place if not necessary to 













MATERIALS AND METHODS 
Human MSC Culture  Mesenchymal precursor cells were provided by Angioblast Systems (New 
York, NY) through an active Materials Transfer Agreement. Human mesenchymal precursor 
cells were isolated to greater than 99% purity from whole aspirates of human bone marrow 
harvested from the iliac crest of healthy adult volunteers aged 18-30, by immunoselection using 
a STRO-3 monoclonal antibody. The STRO-3-bright population was plated in T75 culture flasks 
and expanded in DMEM supplemented with 10% fetal bovine serum.  Selection of the STRO-3 
bright fraction allows for higher purification of MSCs when compared to standard density 
gradient and plating techniques (20).  At fifth passage, MSCs were cultured in DMEM/10% FBS 
with or without 0.1ng/ml TGF-beta (Sigma Aldrich) for seven days either in traditional 
monolayer culture or as described in the scaffold seeding section. 
 
Ovine Cell Preparation The STRO-3 positive MSCs used in this experiment were derived from 
bone marrow aspirates from male crossbred sheep.  Cells were cryopreserved in 42% 
ProfreezeTM/50% Alpha MEM/7.5% DMSO at 225 X 106, 75 X 106, 25 X 106 cells/4ml 
ampoules. Recovery of the frozen preparations was achieved by rapid thawing. The suspension 
was then kept on ice until administered. All animals except for the 450M group received twenty 
mid myocardial (2-3mm depth) BZ injections of 0.2ml (4ml total). The 450M cell group received 
twenty 0.4ml injections (8ml total). 
 
Ovine Echocardiography Protocol and Data Analysis Quantitative two dimensional 
echocardiograms were performed before infarction, after infarction (and after injection) and at 4 
and 8 weeks after infarction.  Images were obtained on a Philips 7500 ultrasound system using a 
5-MHz probe. LV end systolic (LVESV) and end diastolic (LVEDV) volumes were calculated 
using a modified Simpson’s rule. Myocardial infarct length (wall motion abnormality length in 
long axis) was also measured. All image analysis was performed by a blinded analyst. 
 
Hemodynamic Data Collection and Analysis  Arterial blood pressure, LV pressure, central 
venous pressure, pulmonary capillary wedge pressure, maximum ±dP/dt and thermodilution 
cardiac outputs were measured at the same time points that echocardiographic data were 
collected. 
 
Microsphere Assessment of Regional Blood Flow Colored microsphere injection was performed 
at the terminal study to quantify blood flow within infarct and BZ regions. Fifteen million color-
coded, 15.5 µm diameter NuFlow Fluorescent microspheres (IMT Laboratories, Irvine, CA) 
were injected. Reference blood samples were taken during injection.  Myocardial samples and 
reference blood samples were analyzed using flow cytometry for microsphere content by IMT 
Laboratories. 
 
Ovine Tissue Collection and Postmortem Analysis  After euthanasia the LV was opened through 
the septum and a standardized digital photo was taken (Casio EX-Z850, Tokyo Japan). All 
photographs were imported into an image analysis program (Image Pro Plus, Media Cybernetics; 





The infarct area was expressed as a percentage of the left ventricle area.  Representative 
transmural sections of myocardium from the infarct, borderzone, and remote regions were 
harvested and fixed in 10% neutral buffered formalin. Myocardial punch biopsies were also 
obtained, then flash frozen in liquid nitrogen and stored at -80°C.  
 
Ovine Vascular Density Analysis Immunohistochemical staining for the endothelial marker, 
CD31, and smooth muscle actin (SMA) were performed to identify blood vessels in the infarct 
and BZ regions. Corresponding CD31 and SMA slides were used to semiquantitatively assess 
vascular density.  Nine matching 40X fields of view (FOV) from each slide were examined three 
different times and the average number of vessels per 40X field of view was recorded for CD31 
and SMA.  In sheep CD31 effectively stains the endothelium of thin walled venules and 
capillaries but does not reliably stain arterioles and small muscular arteries. SMA staining readily 
identifies arterioles and small muscular arteries in sheep. 
 
Statistical Analysis  Between and within group differences in data were assessed for statistical 
significance. The significance within groups was assessed using repeat measures ANOVA and 
paired t-tests.  Significance between groups was assessed with ANOVA. Data are presented as 
means ± standard error of the mean. Difference in survival was assessed using the chi-squared 
test. 
 
Viscosity Limit of Clinically Available Catheters A system for rheological measurements with 
constant fluid pressure was established, whereby a solution was pushed through each of the 
catheters tested at a constant flow velocity. Dextran solutions of known viscosity (Sigma, at 5, 
10, 20, 25% (w/v) were passed through catheters and the ease with which the solution flowed 
was characterized as ‘easily delivered’ (+), ‘low flow’ (LF), or ‘no flow’ (NF). Viscosities of 
each Dextran solution were then confirmed using an ARES-LS1 Rheometer (TI Instruments), 
using cone-and-plate configuration with diameter of 5 cm, and angular displacement of 0.01 
radians at 1Hz. 
 
Time Dependant Viscosity Profiles Bovine Fibrinogen (Sigma), was dissolved in PBS to yield 1, 
2, 5, 10, and 15% (w/v) solutions. Each of these solutions was loaded into the cone-and-plate 
configured Ares-LS1 Rheometer (TA instruments). Thrombin (Sigma T6200) was reconstituted 
to a concentration of 100U/ml. Diluted thrombin, 50U/ml and 20U/ml was combined with 
fibrinogen at a concentration of 2, 5, or 10% w/v to initiate polymerization to fibrin glue. 
 
Cell viability in fibrin To obtain human mesenchymal stem cells (hMSCs), human bone marrow 
mononuclear cells (LONZA 2M-125) were plated in T75 flasks and cultured in DMEM (Gibco, 
#12430) with 10% FBS (Gibco, # 26140).  The adherent cells were expanded to fourth passage 
for use in all subsequent experiments. hMSCs were encapsulated in fibrin gels at a density of 
4x106cells/cm3.  Fibrin Gels were fabricated by combining 2% w/v fibrinogen with 20U/ml 
thrombin in a 96 well plate. At time points of 0.5, 24 and 72 hours after gel fabrication, gels were 
stained with (LIVE/DEAD, Invitrogen L-3224) and digital images obtained from a fluorescent 
microscope.  Images were then analyzed in Matlab using codes write to allow automated 






Scanning electron microscopy of fibrin hydrogels Fibrinogen from bovine serum was dissolved 
to 2% (w/v) solution, and polymerized with 50 U/ml thrombin to produce 500 µl volume aliquots 
of hydrogels. Hydrogels were placed in sterile water, submerged in liquid nitrogen, freeze dried 
using a lyophilizer (Labconco 7740020), and sputtered-coated with 10 nm Gold-Palladium in a 
Denton Desktop-2 sputtering system. Samples were then mounted onto carbon tape and imaged 
in Hitachi 4700 Scanning Electron Microscope at a range of magnifications between 20 and 
1000x and digitally stored 
 
Animal Model and Quantification of Fibrin-Based Retention Rowett (rnu/rnu) athymic nude rats 
(Harlan Sprague Dawley) were used in studies approved by the Columbia University 
Institutional Animal Care and Use Committee (IACUC). Rats were anesthetized with inhalation 
of isoflurane (2-3%), endotracheally intubated, and mechanically ventilated. The heart was 
exposed through a left thoracotomy and the pericardium incised.  The LAD was then ligated with 
7-0 prolene suture 2-3 mm below the edge of the left atrium. Confluent T75 flasks of fourth 
passage hMSCs were incubated overnight with 10uL of iridium colloid label (Biopal, CL-
300G02-1) prior to injection.  Aliquots of 500,000 labeled hMSCs were suspended either in 300 
µl of PBS (n=6) or a 300 µl mixture of fibrin glue (2% w/v fibrinogen, 20U/ml thrombin, n=6) 
and immediately injected into the borderzone in two divided injections of 150 µL each. Ninety 
minutes after cell injection, the rats were euthanized and the heart, lungs, liver, kidneys, and 
spleen were recovered. Tissue specimens were dehydrated and sent to Biopal for neutron beam 
bombardment and quantification according to manufacturer protocol. 
 
Quantitative PCR Analysis.  Total RNA was isolated by lysing freshly pelleted cells, by an 
RNAqueous isolation kit (Ambion #AM1912).  DNA contamination was enzymatically removed 
(Turbo DNAse, Ambion) and 1 µg of total RNA was used to build a cDNA library with the 
Reaction Ready cDNA Synthesis kit (Superarray Bioscience Corporation) and a Biorad 
MyCycler according to manufacturer specification. Custom RT2Profiler PCR Arrays (Superarray 
Bioscience Corporation, cat# CAPH-0154B) were then run on a Stratagene MX-3005 cycler 
according to manufacturer protocol and analyzed with MxPro v3.0 software.  Fold changes were 
expressed using the ΔΔCt method with normalization of the raw data to the GAPDH 
housekeeper. 
 
Sectioning and Decellularization of Human Myocardium  Surgical explants of patients 
undergoing cardiac transplantation for a diagnosis of nonischemic cardiomyopathy were 
obtained under a Columbia University Medical Center IRB-approved protocol (IRB-
AAAC5633).  A parallel sectioning apparatus (Fig 1c-d) was assembled, with up to six blades, 
each separated by 200mm. Portions of relatively preserved left ventricular myocardium were 
excised and manually sectioned using a parallel assembly of microtome blades (Fisher Scientific, 
#22-030530). Sections were then washed with PBS and trimmed of all epicardial fat. The 
decellularization protocol consisted of 2 hours of lysis in sterile water containing 10mM TRIS 
buffer and 0.1% by weight EDTA followed by 6 hours of solubilization in 0.5% SDS.  
Mechanical agitation in an orbital shaker at 22 oC was used throughout.  After decellularization, 
sections were washed in PBS twice and incubated in PBS containing 50U/ml DNase (Sigma, 
#D4263-5VL) and 1U/ml RNase (Sigma,R4875) at 37 oC then washed in Hank’s Balanced Salt 






Human Mesenchymal Progenitor Cell Isolation and Culture Immunoselected human  
Cell Culture on Hybrid Scaffolds  Circumferential (C) axis sections of decellularized 
myocardium were used for all seeding and implant experiments.  Fully decellularized sections 
were placed singly in 6-well culture plates and 300ul of media containing 106 MSCs was pipetted 
slowly onto the scaffold surface.  After 15 minutes, 5ml of media was added to each well and the 
seeded construct returned to the incubator.  After five days of culture, 106 MSCs suspended in 
300ul PBS containing 2% by weight bovine fibrinogen (Sigma #F8630) and 100U/ml of 
thrombin (Sigma # T6200) was pipette onto the scaffold surface and allowed to polymerize for 3 
minutes.  The seeded construct was then folded in half to yield a final construct with an MSC 
dense fibrin inner layer sandwiched between two outer layers of passively seeded decellularized 
myocardium.  This construct was then placed back in culture for another 48 hours prior to 
implantation. 
 
Cell Culture under Hypoxia and SDF-1 ELISA   One million fifth passage MSCs were plated in 
T75 flasks and cultured for seven days in DMEM/10% FBS supplemented with (0.1ng/ml, 
1.0ng/ml, 10ng/ml) or without TGF-B. Media was changed on the third and sixth days and 
collected for analysis on the seventh day.  The SDF-1 ELISA (R&D Systems) was conducted 
according to the manufacturer’s protocol and the results normalized to cell number to negate 
possible proliferative effects of TGF-beta.  For hypoxia, T75 flasks were placed in an 
environmental chamber (Billups-Rothenberg, Inc) for 24 hours. The chamber was purged for 
15minutes with a mixture containing 93% nitrogen, 5% carbon dioxide, and 2% oxygen at a rate 
of 3L/min and then re-purged after 1 hour to allow equilibration.  Media oxygen tension was 
measured and confirmed to be 2% at 24 hours using an OXY-10 oxygen meter (PreSens, 
Germany). 
 
Matrigel Assay To assess the effect of SDF-1 on vascular network formation of endothelial cells, 
we performed a matrigel assay.  In a 96 well plate, wells were coated with 40-50ml of Matrigel 
(BD) and allowed to polymerize at 37°C. Sixth passage coronary endothelial cells were plated at 
a density of 104 cells/well, with 200ml media (EBM-2, Cambrex), with or without 1.0ng/ml 
SDF-1 (R&D Systems, 350-NS). Network formation was assessed, and pictures (Fig. 4t) 
obtained, at 4, 8, 10 and 24 hours. 
 
Myocardial Infarction and Trilayer Construct Implant Model  Rowett (rnu/rnu) athymic nude 
rats (body weight of 225-250 grams, Harlan Sprague Dawley, Indianapolis, Indiana) were used 
in studies approved by the Columbia University Institutional Animal Care and Use Committee. 
Rats were anesthetized with inhaled isoflurane (2-3%), endotracheally intubated, and 
mechanically ventilated.  The heart was exposed through a left thoracotomy and the pericardium 
incised.  The LAD was then ligated with 7-0 prolene suture 2-3 mm below the edge of the left 
atrium.  The engineered patch was then sutured directly onto the epicardial surface of the infarct 
bed using four 7-0 prolene stay sutures.  Following patch implant the ribs were reapproximated 
and the soft tissue closed in two layers.  Four weeks after patch implant, rats were sacrificed and 
intact hearts collected for histology. 
 
DNA Quantification in Native and Decellularized Myocardial Tissue To determine the extent of 
decellularization, residual DNA in a decellularized tissue sample was quantified and compared to 





decellularized).  The samples were first minced and then digested for 16 hours at 50 oC in 1 ml of 
a 0.1 mg/ml solution of Proteinase-K (Fisher) in TEX (10 mM Tris-HCL, 1 mM EDTA, 0.1% 
TritonX-100).  After digestion, the samples were centrifuged at 500 RPM (Eppendorf Centrifuge 
5804R) and 250 ml of supernatant from each sample was transferred to a clean tube.  100ul of 
each sample was plated in duplicate on a 96 well plate.  DNA content of native myocardium and 
decellularized samples was then quantified using a Quant-it Picogreen Assay Kit (Invitrogen, 
P7589) according to manufacturer protocol.  Plates were read on a BioTek Flx800 
spectrophotometer.  
 
Scanning Electron Microscopy of Decellularized Tissue Samples to be imaged by SEM were 
first dehydrated by ethanol gradient and then by critical point drying in a Balzers Baltec030.  The 
samples were mounted on a stage by carbon tape, sputter coated with 15nm of Gold-Palladium in 
a Denton Desktop-2 sputtering system, and imaged in a Hitachi 4700 Scanning Electron 
Microscope at a range of magnifications between 30 and 4000x. Images were digitally stored. 
 
Immunohistochemistry of Decellularized and Implanted Tissue  Specimens were fixed overnight 
in 10% formalin prior to paraffin embedding. To quantify capillary density, sections were stained 
with MAbs directed against rat factor VIII (Dako, Carpinteria, CA). Arterioles were 
differentiated from large capillaries by the presence of a smooth muscle layer, identified by 
staining with a monoclonal antibody against smooth muscle actin (Biogenex, San Ramon, CA).  
Staining was performed by immunoperoxidase technique using an avidin-biotin blocking kit, a 
rat-absorbed biotinylated anti-mouse IgG, and a peroxidase conjugate (all obtained from Vector 
Laboratories, Burlingame, CA).   
 
Uniaxial Tensile Testing of Myocardial Samples  A cardioplegic solution containing (mmol/l): 
Na+ 152, K+ 3.6, Cl- 135, HCO3- 25, H2PO4- 1.3, SO42- 0.6, Mg2+ 0.6, Ca2+ 2.5, glucose 11.2, 2,3-
butanedione monoxime 30 and 10 IU/l insulin was prepared as previously described (30). 
Samples excised from freshly explanted hearts were processed to obtain rectangular 
circumferential and radial sections (measuring approximately 70mm x 6mm x 0.3mm) as 
described above. These sections were immediately placed in the cardioplegic solution, while 
every other section, obtained by sectioning with the parallel blade array, was processed for 
decellularization. Following 15 minutes in cardioplegic solution, fresh sections were subject to 
tensile testing using an Instron 5848 Microtester. Both radial and circumferential sections were 
uniaxially loaded by applying force to the samples in the apex-to-base directions (Fig 2m, z-
axis). Samples were stretched at a rate of 0.1% tensile strength per second, up to 20% strain. The 
tangential moduli at 20% strain was calculated using data from 19% to 20% strain. The same 
mechanical testing protocol was later used to test decellularized tissue samples. 
 
Quantitative PCR Analysis  Total RNA was isolated by lysing freshly pelleted cells using an 
an RNAqueous isolation kit (Ambion, Austin, TX).  DNA contamination was enzymatically 
removed (Turbo DNAse, Ambion) and 1 microgram of total RNA was used to build a cDNA 
library with the Reaction Ready cDNA Synthesis kit (Superarray Bioscience Corporation, 
Frederick, MD) and a Biorad MyCycler according to manufacturer specification.  Custom 
RT2Profiler PCR Arrays (Superarray Bioscience Corporation, cat# CAPH-0154B) were then run 





v3.0 software.  Fold changes were expressed using the DCt method with normalization of the raw 
data to the RPL32 housekeeper. 
 
Western Blots  MSCs (P5) were seeded at 1 x 106 cells / 100-mm dish and cultured in DMEM 
with / without TGF (0.1, 1, 10 ng/ml) for 7 days . Cells were then rinsed with ice-cold PBS and 
lysed using MPER lysis buffer (Pierce) containing 1mM phenylmethyl sulfonyl fluoride (PMSF) 
and Complete Protease Inhibitors (Roche).  After scraping, cell debris was pelleted.  Western 
blotting was performed using 12% NuPAGE Bis-Tris gel with MES buffer (Invitrogen), 
transferred to nitrocellulose membranes (Invitrogen), and incubation with anti-SDF-1 antibodies 
(Abcam).  Protein signal was detected using ECL reagent (GE Healthcare) and exposed to X-ray 
film. 
 
Bilayer Scaffold Echocardiography We performed echocardiography using inhaled isoflurane 
(2%) anesthesia as described previously with a Sonos 5500 system (Philips Medical Systems, 
Andover, Massachusetts) using a broadband high frequency (12-MHz) transducer (S12). Each rat 
was scanned with two-dimensional imaging and M-mode imaging in parasternal short axis view. 
LV fractional shortening (FS) was calculated using the following formula: 
 
FS (%) = (LVDd-LVDs)/LVDd×100 
 
where, LVDd is the LV diastolic diameter and LVDs is the LV systolic diameter. Fractional area 
change (FAC) was also calculated using the following formula: 
 
FAC (%) = (LVDA-LVSA)/LVDA×100 
 
where LVDA is the LV diastolic area and LVSA is the LV systolic area, each measured at the 
mid-papillary level. The maximum and minimum values in 1 cardiac cycle were obtained by an 
experienced observer manually tracing the endocardial border of the LV. 
A total of 60 rats underwent LAD ligation.  Baseline echocardiography in survivors (n=45) was 
conducted three days after LAD ligation and animals were randomized to receive no further 
intervention, 1 million TGF-beta conditioned MSCs by intramyocardial injection, or 1 million 
TGF-beta conditioned MSCs delivered as a bilayer composite scaffold (n=15 per group) 7 days 
post LAD ligation.  Repeat echocardiography was conducted six weeks after LAD ligation in all 
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